| pubmed-article:17768387 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17768387 | lifeskim:mentions | umls-concept:C0008059 | lld:lifeskim |
| pubmed-article:17768387 | lifeskim:mentions | umls-concept:C0013080 | lld:lifeskim |
| pubmed-article:17768387 | lifeskim:mentions | umls-concept:C0018956 | lld:lifeskim |
| pubmed-article:17768387 | lifeskim:mentions | umls-concept:C0085669 | lld:lifeskim |
| pubmed-article:17768387 | lifeskim:mentions | umls-concept:C1504389 | lld:lifeskim |
| pubmed-article:17768387 | lifeskim:mentions | umls-concept:C0035020 | lld:lifeskim |
| pubmed-article:17768387 | lifeskim:mentions | umls-concept:C0162643 | lld:lifeskim |
| pubmed-article:17768387 | lifeskim:mentions | umls-concept:C0600688 | lld:lifeskim |
| pubmed-article:17768387 | lifeskim:mentions | umls-concept:C0205164 | lld:lifeskim |
| pubmed-article:17768387 | lifeskim:mentions | umls-concept:C1524003 | lld:lifeskim |
| pubmed-article:17768387 | pubmed:issue | 10 | lld:pubmed |
| pubmed-article:17768387 | pubmed:dateCreated | 2007-10-31 | lld:pubmed |
| pubmed-article:17768387 | pubmed:abstractText | We report a retrospective analysis of 11 children with Down syndrome (DS) treated by SCT in eight German/Austrian SCT centres. Indications for transplantation were acute lymphoblastic leukaemia (N=8) and acute myeloid leukaemia (N=3). A reduced intensity conditioning (RIC) containing 2 Gy TBI was given to two patients, another five received a myeloablative regimen with 12 Gy TBI. Treosulphan or busulphan was used in the remaining four children. Four of eleven (36%) patients are alive. All of them were treated with a myeloablative regimen. One of the four surviving children relapsed 9 months after SCT and is currently receiving palliative outpatient treatment. The main cause of death was relapse (5/11). Two children died of regimen-related toxicity (RRT), one from severe exfoliative dermatitis and multiorgan failure after a treosulphan-containing regimen, the other from GvHD-related infections after RIC. Acute GvHD of the skin was observed in 10 of 10 evaluable patients, and chronic GvHD in 4 of 8. Our data show that DS patients can tolerate commonly used, fully myeloablative preparative regimens. The major cause of death is relapse rather than RRT resulting in an event-free survival of 18% and over all survival of 36%. | lld:pubmed |
| pubmed-article:17768387 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17768387 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17768387 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17768387 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17768387 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:17768387 | pubmed:issn | 0268-3369 | lld:pubmed |
| pubmed-article:17768387 | pubmed:author | pubmed-author:FuchsDD | lld:pubmed |
| pubmed-article:17768387 | pubmed:author | pubmed-author:ZintlFF | lld:pubmed |
| pubmed-article:17768387 | pubmed:author | pubmed-author:SauerMM | lld:pubmed |
| pubmed-article:17768387 | pubmed:author | pubmed-author:SykoraK WKW | lld:pubmed |
| pubmed-article:17768387 | pubmed:author | pubmed-author:PetersCC | lld:pubmed |
| pubmed-article:17768387 | pubmed:author | pubmed-author:WelteKK | lld:pubmed |
| pubmed-article:17768387 | pubmed:author | pubmed-author:FriedrichWW | lld:pubmed |
| pubmed-article:17768387 | pubmed:author | pubmed-author:MeissnerBB | lld:pubmed |
| pubmed-article:17768387 | pubmed:author | pubmed-author:DillonEE | lld:pubmed |
| pubmed-article:17768387 | pubmed:author | pubmed-author:Handgretinger... | lld:pubmed |
| pubmed-article:17768387 | pubmed:author | pubmed-author:VormoorJJ | lld:pubmed |
| pubmed-article:17768387 | pubmed:author | pubmed-author:BorkhardtAA | lld:pubmed |
| pubmed-article:17768387 | pubmed:author | pubmed-author:SchrauderAA | lld:pubmed |
| pubmed-article:17768387 | pubmed:author | pubmed-author:MaeckerBB | lld:pubmed |
| pubmed-article:17768387 | pubmed:author | pubmed-author:SchusterF RFR | lld:pubmed |
| pubmed-article:17768387 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17768387 | pubmed:volume | 40 | lld:pubmed |
| pubmed-article:17768387 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17768387 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17768387 | pubmed:pagination | 945-9 | lld:pubmed |
| pubmed-article:17768387 | pubmed:meshHeading | pubmed-meshheading:17768387... | lld:pubmed |
| pubmed-article:17768387 | pubmed:meshHeading | pubmed-meshheading:17768387... | lld:pubmed |
| pubmed-article:17768387 | pubmed:meshHeading | pubmed-meshheading:17768387... | lld:pubmed |
| pubmed-article:17768387 | pubmed:meshHeading | pubmed-meshheading:17768387... | lld:pubmed |
| pubmed-article:17768387 | pubmed:meshHeading | pubmed-meshheading:17768387... | lld:pubmed |
| pubmed-article:17768387 | pubmed:meshHeading | pubmed-meshheading:17768387... | lld:pubmed |
| pubmed-article:17768387 | pubmed:meshHeading | pubmed-meshheading:17768387... | lld:pubmed |
| pubmed-article:17768387 | pubmed:meshHeading | pubmed-meshheading:17768387... | lld:pubmed |
| pubmed-article:17768387 | pubmed:meshHeading | pubmed-meshheading:17768387... | lld:pubmed |
| pubmed-article:17768387 | pubmed:meshHeading | pubmed-meshheading:17768387... | lld:pubmed |
| pubmed-article:17768387 | pubmed:meshHeading | pubmed-meshheading:17768387... | lld:pubmed |
| pubmed-article:17768387 | pubmed:meshHeading | pubmed-meshheading:17768387... | lld:pubmed |
| pubmed-article:17768387 | pubmed:meshHeading | pubmed-meshheading:17768387... | lld:pubmed |
| pubmed-article:17768387 | pubmed:meshHeading | pubmed-meshheading:17768387... | lld:pubmed |
| pubmed-article:17768387 | pubmed:meshHeading | pubmed-meshheading:17768387... | lld:pubmed |
| pubmed-article:17768387 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17768387 | pubmed:articleTitle | Relapse, not regimen-related toxicity, was the major cause of treatment failure in 11 children with Down syndrome undergoing haematopoietic stem cell transplantation for acute leukaemia. | lld:pubmed |
| pubmed-article:17768387 | pubmed:affiliation | Department of Paediatric Haematology and Oncology, Hannover Medical School, Hannover, Germany. | lld:pubmed |
| pubmed-article:17768387 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17768387 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17768387 | lld:pubmed |
